nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors.
Andrew J WagnerVinod RaviRichard F RiedelKristen GanjooBrian Andrew Van TineRashmi ChughLee CranmerErlinda M GordonJason L HornickHeng DuBerta GrigorianAnita N SchmidShihe HouKatherine HarrisDavid J KwiatkowskiNeil P DesaiMark A DicksonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
nab-Sirolimus is active in patients with malignant PEComa. The response rate, durability of response, disease control rate, and safety profile support that nab-sirolimus represents an important new treatment option for this disease.